{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:54:49Z","timestamp":1792173289388,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11060-020-03598-2","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T08:02:44Z","timestamp":1597824164000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor"],"prefix":"10.1007","volume":"151","author":[{"given":"Kelly M.","family":"Hotchkiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0104-7658","authenticated-orcid":false,"given":"John H.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"issue":"Suppl 4","key":"3598_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011. Neuro-oncology 16(Suppl 4):iv1\u2013iv63. https:\/\/doi.org\/10.1093\/neuonc\/nou223","journal-title":"Neuro-oncology"},{"key":"3598_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"3598_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020174","author":"D Fabian","year":"2019","unstructured":"Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, Gonzalez J, Palmer JD (2019) Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers. https:\/\/doi.org\/10.3390\/cancers11020174","journal-title":"Cancers"},{"key":"3598_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1586\/erv.11.177","volume":"11","author":"CA Del Vecchio","year":"2012","unstructured":"Del Vecchio CA, Li G, Wong AJ (2012) Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines 11:133\u2013144. https:\/\/doi.org\/10.1586\/erv.11.177","journal-title":"Expert Rev Vaccines"},{"key":"3598_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/imt.15.39","volume":"7","author":"MR Neagu","year":"2015","unstructured":"Neagu MR, Reardon DA (2015) Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? Immunotherapy 7:603\u2013606. https:\/\/doi.org\/10.2217\/imt.15.39","journal-title":"Immunotherapy"},{"key":"3598_CR6","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1158\/1078-0432.CCR-14-0832","volume":"20","author":"PE Fecci","year":"2014","unstructured":"Fecci PE, Heimberger AB, Sampson JH (2014) Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res 20:5620\u20135629. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0832","journal-title":"Clin Cancer Res"},{"key":"3598_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11060-014-1502-6","volume":"119","author":"ET Sayegh","year":"2014","unstructured":"Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT (2014) Vaccine therapies for patients with glioblastoma. J Neurooncol 119:531\u2013546. https:\/\/doi.org\/10.1007\/s11060-014-1502-6","journal-title":"J Neurooncol"},{"key":"3598_CR8","doi-asserted-by":"publisher","first-page":"iii21","DOI":"10.1093\/neuonc\/nox036.071","volume":"19","author":"D Reardon","year":"2017","unstructured":"Reardon D, Omuro A, Brandes A, Rieger J, Wick A, Sepulveda J, Phuphanich S, De Souza P, Ahluwalia M, Lim M (2017) OS10. 3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncology 19:iii21\u2013iii21","journal-title":"Neuro-Oncology"},{"key":"3598_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"3598_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"3598_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","volume":"17","author":"DJ Ma","year":"2015","unstructured":"Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN (2015) A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neurooncology 17:1261\u20131269. https:\/\/doi.org\/10.1093\/neuonc\/nou328","journal-title":"Neurooncology"},{"key":"3598_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12:623\u2013635. https:\/\/doi.org\/10.1038\/nri3265","journal-title":"Nat Rev Immunol"},{"key":"3598_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1182\/blood-2005-01-0154","volume":"107","author":"E Hatterer","year":"2006","unstructured":"Hatterer E, Davoust N, Didier-Bazes M, Vuaillat C, Malcus C, Belin MF, Nataf S (2006) How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107:806\u2013812. https:\/\/doi.org\/10.1182\/blood-2005-01-0154","journal-title":"Blood"},{"key":"3598_CR14","doi-asserted-by":"publisher","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","volume":"4","author":"JJ Iliff","year":"2012","unstructured":"Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 4:147ra111. https:\/\/doi.org\/10.1126\/scitranslmed.3003748","journal-title":"Sci Transl Med"},{"key":"3598_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1084\/jem.20142290","volume":"212","author":"A Aspelund","year":"2015","unstructured":"Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212:991\u2013999. https:\/\/doi.org\/10.1084\/jem.20142290","journal-title":"J Exp Med"},{"issue":"Suppl 7","key":"3598_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/neuonc\/nov151","volume":"17","author":"EK Nduom","year":"2015","unstructured":"Nduom EK, Weller M, Heimberger AB (2015) Immunosuppressive mechanisms in glioblastoma. Neuro-oncology 17(Suppl 7):9\u201314. https:\/\/doi.org\/10.1093\/neuonc\/nov151","journal-title":"Neuro-oncology"},{"key":"3598_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","volume":"23","author":"JE Ohm","year":"2001","unstructured":"Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23:263\u2013272. https:\/\/doi.org\/10.1385\/IR:23:2-3:263","journal-title":"Immunol Res"},{"key":"3598_CR18","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1007\/s11033-010-0469-4","volume":"38","author":"B Qiu","year":"2011","unstructured":"Qiu B, Zhang D, Wang C, Tao J, Tie X, Qiao Y, Xu K, Wang Y, Wu A (2011) IL-10 and TGF-beta2 are overexpressed in tumor spheres cultured from human gliomas. Mol Biol Rep 38:3585\u20133591. https:\/\/doi.org\/10.1007\/s11033-010-0469-4","journal-title":"Mol Biol Rep"},{"key":"3598_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA (2017) The microenvironmental landscape of brain tumors. Cancer Cell 31:326\u2013341. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.009","journal-title":"Cancer Cell"},{"key":"3598_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/neuonc\/now176","volume":"19","author":"M Wahl","year":"2017","unstructured":"Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM (2017) Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neurooncology 19:242\u2013251. https:\/\/doi.org\/10.1093\/neuonc\/now176","journal-title":"Neurooncology"},{"key":"3598_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"3598_CR22","doi-asserted-by":"publisher","first-page":"11499","DOI":"10.1158\/0008-5472.CAN-07-5312","volume":"67","author":"MM Alonso","year":"2007","unstructured":"Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J (2007) Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 67:11499\u201311504. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5312","journal-title":"Cancer Res"},{"key":"3598_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"J Zhang","year":"2012","unstructured":"Zhang J, Stevens MF, Bradshaw TD (2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5:102\u2013114","journal-title":"Curr Mol Pharmacol"},{"key":"3598_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3:198\u2013210. https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007","journal-title":"Genes Dis"},{"key":"3598_CR25","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1212\/01.wnl.0000127617.89363.84","volume":"62","author":"W Wick","year":"2004","unstructured":"Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on\/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113\u20132115. https:\/\/doi.org\/10.1212\/01.wnl.0000127617.89363.84","journal-title":"Neurology"},{"key":"3598_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/sj.bjc.6603376","volume":"95","author":"AA Brandes","year":"2006","unstructured":"Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crino L, Ermani M, Gicno (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155\u20131160. https:\/\/doi.org\/10.1038\/sj.bjc.6603376","journal-title":"Br J Cancer"},{"key":"3598_CR27","first-page":"3467","volume":"33","author":"A Darlix","year":"2013","unstructured":"Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P, Taillandier L (2013) Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res 33:3467\u20133474","journal-title":"Anticancer Res"},{"key":"3598_CR28","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1200\/JCO.2007.10.7722","volume":"25","author":"A Wick","year":"2007","unstructured":"Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357\u20133361. https:\/\/doi.org\/10.1200\/JCO.2007.10.7722","journal-title":"J Clin Oncol"},{"key":"3598_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-015-1834-x","volume":"124","author":"G Welzel","year":"2015","unstructured":"Welzel G, Gehweiler J, Brehmer S, Appelt JU, von Deimling A, Seiz-Rosenhagen M, Schmiedek P, Wenz F, Giordano FA (2015) Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis. J Neurooncol 124:265\u2013273. https:\/\/doi.org\/10.1007\/s11060-015-1834-x","journal-title":"J Neurooncol"},{"key":"3598_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS (2016) Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 13:659\u2013673. https:\/\/doi.org\/10.1038\/nrclinonc.2016.64","journal-title":"Nat Rev Clin Oncol"},{"key":"3598_CR31","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S1470-2045(13)70056-1","volume":"14","author":"N Andre","year":"2013","unstructured":"Andre N, Banavali S, Snihur Y, Pasquier E (2013) Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 14:e239\u2013e248. https:\/\/doi.org\/10.1016\/S1470-2045(13)70056-1","journal-title":"Lancet Oncol"},{"key":"3598_CR32","first-page":"1117","volume":"16","author":"DS Kong","year":"2006","unstructured":"Kong DS, Lee JI, Kim WS, Son MJ, Lim DH, Kim ST, Park K, Kim JH, Eoh W, Nam DH (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16:1117\u20131121","journal-title":"Oncol Rep"},{"key":"3598_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw261","author":"JL Gulley","year":"2017","unstructured":"Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG (2017) Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djw261","journal-title":"J Natl Cancer Inst"},{"key":"3598_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/mutage\/17.6.483","volume":"17","author":"GP Margison","year":"2002","unstructured":"Margison GP, Santibanez Koref MF, Povey AC (2002) Mechanisms of carcinogenicity\/chemotherapy by O6-methylguanine. Mutagenesis 17:483\u2013487. https:\/\/doi.org\/10.1093\/mutage\/17.6.483","journal-title":"Mutagenesis"},{"key":"3598_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2019.00041","volume":"9","author":"P Daniel","year":"2019","unstructured":"Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS (2019) Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol 9:41. https:\/\/doi.org\/10.3389\/fonc.2019.00041","journal-title":"Front Oncol"},{"key":"3598_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrc3342","volume":"12","author":"P Bouwman","year":"2012","unstructured":"Bouwman P, Jonkers J (2012) The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 12:587\u2013598. https:\/\/doi.org\/10.1038\/nrc3342","journal-title":"Nat Rev Cancer"},{"key":"3598_CR37","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ng.3590","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DI, Zairis S, Abate F, Liu Z, Elliott O, Shin YJ, Lee JK, Lee IH, Park WY, Eoli M, Blumberg AJ, Lasorella A, Nam DH, Finocchiaro G, Iavarone A, Rabadan R (2016) Clonal evolution of glioblastoma under therapy. Nat Genet 48:768\u2013776. https:\/\/doi.org\/10.1038\/ng.3590","journal-title":"Nat Genet"},{"key":"3598_CR38","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-18-1892","volume":"25","author":"S Indraccolo","year":"2019","unstructured":"Indraccolo S, Lombardi G, Fassan M, Pasqualini L, Giunco S, Marcato R, Gasparini A, Candiotto C, Nalio S, Fiduccia P, Fanelli GN, Pambuku A, Della Puppa A, D\u2019Avella D, Bonaldi L, Gardiman MP, Bertorelle R, De Rossi A, Zagonel V (2019) Genetic, epigenetic, and immunologic profiling of MMR-deficient relapsed glioblastoma. Clin Cancer Res 25:1828\u20131837. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1892","journal-title":"Clin Cancer Res"},{"key":"3598_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","volume":"343","author":"BE Johnson","year":"2014","unstructured":"Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189\u2013193. https:\/\/doi.org\/10.1126\/science.1239947","journal-title":"Science"},{"key":"3598_CR40","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/neuonc\/noy016","volume":"20","author":"S Choi","year":"2018","unstructured":"Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF (2018) Temozolomide-associated hypermutation in gliomas. Neurooncology 20:1300\u20131309. https:\/\/doi.org\/10.1093\/neuonc\/noy016","journal-title":"Neurooncology"},{"key":"3598_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-015-1403-6","volume":"129","author":"HF van Thuijl","year":"2015","unstructured":"van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmstrom A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmalm M, Lamfers ML, Saito N, Aburatani H, Mukasa A, Berger MS, Soderkvist P, Taylor BS, Molinaro AM, Wesseling P, Reijneveld JC, Chang SM, Ylstra B, Costello JF (2015) Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol 129:597\u2013607. https:\/\/doi.org\/10.1007\/s00401-015-1403-6","journal-title":"Acta Neuropathol"},{"key":"3598_CR42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1593\/tlo.12253","volume":"5","author":"CK Park","year":"2012","unstructured":"Park CK, Kim JE, Kim JY, Song SW, Kim JW, Choi SH, Kim TM, Lee SH, Kim IH, Park SH (2012) The changes in MGMT promoter methylation status in initial and recurrent glioblastomas. Transl Oncol 5:393\u2013397. https:\/\/doi.org\/10.1593\/tlo.12253","journal-title":"Transl Oncol"},{"key":"3598_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ijc.26083","volume":"129","author":"J Felsberg","year":"2011","unstructured":"Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Loffler M, Weller M, Reifenberger G, Tonn JC, German Glioma N (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129:659\u2013670. https:\/\/doi.org\/10.1002\/ijc.26083","journal-title":"Int J Cancer"},{"key":"3598_CR44","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/s41388-020-1208-5","volume":"39","author":"N Struve","year":"2020","unstructured":"Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, Ott L, Muller-Goebel J, Weik AS, Hoffer K, Krug L, Rieckmann T, Bussmann L, Henze M, Morrissette JJD, Kurian KM, Schuller U, Petersen C, Rothkamm K, DM OR, Short SC, Kriegs M (2020) EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Oncogene 39:3041\u20133055. https:\/\/doi.org\/10.1038\/s41388-020-1208-5","journal-title":"Oncogene"},{"key":"3598_CR45","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346\u20132357. https:\/\/doi.org\/10.1200\/JCO.2005.00.240","journal-title":"J Clin Oncol"},{"key":"3598_CR46","doi-asserted-by":"publisher","first-page":"e1434464","DOI":"10.1080\/2162402X.2018.1434464","volume":"7","author":"CM Suryadevara","year":"2018","unstructured":"Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE 2, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L (2018) Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology 7:e1434464. https:\/\/doi.org\/10.1080\/2162402X.2018.1434464","journal-title":"Oncoimmunology"},{"key":"3598_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1215\/15228517-2007-046","volume":"10","author":"AB Heimberger","year":"2008","unstructured":"Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH (2008) Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neurooncology 10:98\u2013103. https:\/\/doi.org\/10.1215\/15228517-2007-046","journal-title":"Neurooncology"},{"key":"3598_CR48","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cncr.25035","volume":"116","author":"B Neyns","year":"2010","unstructured":"Neyns B, Tosoni A, Hwu WJ, Reardon DA (2010) Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 116:2868\u20132877. https:\/\/doi.org\/10.1002\/cncr.25035","journal-title":"Cancer"},{"key":"3598_CR49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-017-2668-5","volume":"136","author":"AJ Lin","year":"2018","unstructured":"Lin AJ, Campian JL, Hui C, Rudra S, Rao YJ, Thotala D, Hallahan D, Huang J (2018) Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol 136:403\u2013411. https:\/\/doi.org\/10.1007\/s11060-017-2668-5","journal-title":"J Neurooncol"},{"key":"3598_CR50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/neuonc\/noq204","volume":"13","author":"CE Fadul","year":"2011","unstructured":"Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS (2011) Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neurooncology 13:393\u2013400. https:\/\/doi.org\/10.1093\/neuonc\/noq204","journal-title":"Neurooncology"},{"key":"3598_CR51","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","volume":"22","author":"YB Su","year":"2004","unstructured":"Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610\u2013616. https:\/\/doi.org\/10.1200\/JCO.2004.07.060","journal-title":"J Clin Oncol"},{"key":"3598_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/0008-5472.CAN-06-3712","volume":"67","author":"M Briegert","year":"2007","unstructured":"Briegert M, Kaina B (2007) Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res 67:26\u201331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3712","journal-title":"Cancer Res"},{"key":"3598_CR53","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00262-009-0671-1","volume":"58","author":"C Banissi","year":"2009","unstructured":"Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 58:1627\u20131634. https:\/\/doi.org\/10.1007\/s00262-009-0671-1","journal-title":"Cancer Immunol Immunother"},{"key":"3598_CR54","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/neuonc\/noz015","volume":"21","author":"A Karachi","year":"2019","unstructured":"Karachi A, Yang C, Dastmalchi F, Sayour EJ, Huang J, Azari H, Long Y, Flores C, Mitchell DA, Rahman M (2019) Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neurooncology 21:730\u2013741. https:\/\/doi.org\/10.1093\/neuonc\/noz015","journal-title":"Neurooncology"},{"key":"3598_CR55","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/neuonc\/noq157","volume":"13","author":"JH Sampson","year":"2011","unstructured":"Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neurooncology 13:324\u2013333. https:\/\/doi.org\/10.1093\/neuonc\/noq157","journal-title":"Neurooncology"},{"key":"3598_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12885-019-5308-y","volume":"19","author":"S Heynckes","year":"2019","unstructured":"Heynckes S, Daka K, Franco P, Gaebelein A, Frenking JH, Doria-Medina R, Mader I, Delev D, Schnell O, Heiland DH (2019) Crosslink between temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme. BMC Cancer 19:117. https:\/\/doi.org\/10.1186\/s12885-019-5308-y","journal-title":"BMC Cancer"},{"key":"3598_CR57","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1182\/blood-2011-02-334565","volume":"118","author":"DA Mitchell","year":"2011","unstructured":"Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH (2011) Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 118:3003\u20133012. https:\/\/doi.org\/10.1182\/blood-2011-02-334565","journal-title":"Blood"},{"key":"3598_CR58","doi-asserted-by":"publisher","first-page":"e31046","DOI":"10.1371\/journal.pone.0031046","volume":"7","author":"JH Sampson","year":"2012","unstructured":"Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Mitchell DA (2012) A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS ONE 7:e31046. https:\/\/doi.org\/10.1371\/journal.pone.0031046","journal-title":"PLoS ONE"},{"key":"3598_CR59","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1128\/CVI.00292-09","volume":"17","author":"TG Kim","year":"2010","unstructured":"Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, Hong YK (2010) Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 17:143\u2013153. https:\/\/doi.org\/10.1128\/CVI.00292-09","journal-title":"Clin Vaccine Immunol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-020-03598-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T19:08:24Z","timestamp":1629313704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-020-03598-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3598"],"URL":"https:\/\/doi.org\/10.1007\/s11060-020-03598-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors do not have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}